Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nanobiotix ADR Representing Ord Shs NBTX

Healthcare Biotechnology
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and... see more

Recent & Breaking News (NDAQ:NBTX)

Voting Rights and Shares Capital of the Company

GlobeNewswire December 8, 2022

NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 15, 2022

NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer

GlobeNewswire November 14, 2022

NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire November 10, 2022

NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update

GlobeNewswire November 9, 2022

NANOBIOTIX Voting Rights and Shares Capital of the Company

GlobeNewswire November 8, 2022

NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3

GlobeNewswire November 2, 2022

NANOBIOTIX to Present at the Jefferies London Healthcare Conference

GlobeNewswire October 31, 2022

NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022

GlobeNewswire October 27, 2022

NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank

GlobeNewswire October 18, 2022

Nanobiotix: Voting Rights and Shares Capital of the Company

Business Wire October 10, 2022

Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022

Business Wire September 22, 2022

Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Business Wire September 21, 2022

Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024

Business Wire September 12, 2022

Nanobiotix: Voting Rights and Shares Capital of the Company

Business Wire September 8, 2022

NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Business Wire September 7, 2022

NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences

Business Wire September 6, 2022

Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022

Business Wire August 31, 2022

NANOBIOTIX: Voting Rights and Shares Capital of the Company

Business Wire August 9, 2022

Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont

Business Wire July 13, 2022